These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
395 related articles for article (PubMed ID: 11104391)
21. Evaluating the bioavailability and bioequivalence of generic medications. Howland RH J Psychosoc Nurs Ment Health Serv; 2010 Jan; 48(1):13-6. PubMed ID: 20102127 [TBL] [Abstract][Full Text] [Related]
22. Sample size calculation for the Power Model for dose proportionality studies. Sethuraman VS; Leonov S; Squassante L; Mitchell TR; Hale MD Pharm Stat; 2007; 6(1):35-41. PubMed ID: 17323313 [TBL] [Abstract][Full Text] [Related]
23. A method for the evaluation of individual bioequivalence. Endrenyi L Int J Clin Pharmacol Ther; 1994 Sep; 32(9):497-508. PubMed ID: 7820334 [TBL] [Abstract][Full Text] [Related]
24. [Bioequivalence and generic drugs. I. Studies of bioequivalence, considering the theoretical basis, design and use]. Zapater P; Horga JF Rev Neurol; 1999 Dec 16-31; 29(12):1235-46. PubMed ID: 10652753 [TBL] [Abstract][Full Text] [Related]
25. Bioequivalence studies for levothyroxine. Bolton S AAPS J; 2005 Mar; 7(1):E47-53. PubMed ID: 16146349 [TBL] [Abstract][Full Text] [Related]
26. Variability and impact on design of bioequivalence studies. Van Peer A Basic Clin Pharmacol Toxicol; 2010 Mar; 106(3):146-53. PubMed ID: 20041877 [TBL] [Abstract][Full Text] [Related]
27. Types of bioequivalence and related statistical considerations. Hauck WW; Anderson S Int J Clin Pharmacol Ther Toxicol; 1992 May; 30(5):181-7. PubMed ID: 1592546 [TBL] [Abstract][Full Text] [Related]
28. Viewpoint: observations on scaled average bioequivalence. Patterson SD; Jones B Pharm Stat; 2012; 11(1):1-7. PubMed ID: 22162308 [TBL] [Abstract][Full Text] [Related]
30. What makes a generic medication generic? Howland RH J Psychosoc Nurs Ment Health Serv; 2009 Dec; 47(12):17-20. PubMed ID: 20000278 [TBL] [Abstract][Full Text] [Related]
32. On statistical power for average bioequivalence testing under replicated crossover designs. Wan H; Chow SC J Biopharm Stat; 2002 Aug; 12(3):295-309. PubMed ID: 12448572 [TBL] [Abstract][Full Text] [Related]
33. Individual bioequivalence testing under 2x3 designs. Chow SC; Shao J; Wang H Stat Med; 2002 Mar; 21(5):629-48. PubMed ID: 11870806 [TBL] [Abstract][Full Text] [Related]
34. Sample size considerations for establishing clinical bioequivalence of allergen formulations. Rabin RL; Slater JE; Lachenbruch P; Pastor RW Arb Paul Ehrlich Inst Bundesamt Sera Impfstoffe Frankf A M; 2003; (94):24-33. PubMed ID: 15119019 [TBL] [Abstract][Full Text] [Related]
35. Modified Regulatory Pathways to Approve Generic Drugs in the US and a Systematic Review of Their Outcomes. Kesselheim AS; Polinski JM; Fulchino LA; Isaman DL; Gagne JJ Drugs; 2015 Apr; 75(6):633-50. PubMed ID: 25822610 [TBL] [Abstract][Full Text] [Related]
36. Requirements for submission of bioequivalence data; final rule. Final rule. Food and Drug Administration, HHS Fed Regist; 2009 Jan; 74(11):2849-62. PubMed ID: 19385107 [TBL] [Abstract][Full Text] [Related]
37. The bootstrap procedure in individual bioequivalence. Shao J; Chow SC; Wang B Stat Med; 2000 Oct; 19(20):2741-54. PubMed ID: 11033572 [TBL] [Abstract][Full Text] [Related]
40. An alternative approach to assess exchangeability of a test treatment and the standard treatment with normally distributed response. Tsong Y; Shen M J Biopharm Stat; 2007; 17(2):329-38. PubMed ID: 17365227 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]